Skip to main content
  • Pretreatment with PY212 Inhibitors Led to Better MACE Outcomes in STEMI Patients Undergoing PPCI – Spanish Registry Study

    Patients pretreated with P2Y12 inhibitors before undergoing primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) saw a significant reduction in major cardiac events without increased bleeding risk in a new study of a regional Spanish registry published Monday online.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details